The evolution of research and development in the pharmaceutical industry: Toward the open innovation model - Can pharma reinvent itself?

Ram Subramanian, Jeffrey H. Toney, C. Jayachandran

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

The global pharmaceutical industry is facing diminishing returns from its massive investment in research and development. This is particularly troublesome because the industry has long enjoyed monopoly rents that come from innovative new drugs. The purpose of this paper is to examine the extant R&D practices in the industry and make a strong case for a shift to the open innovation model. Potential roadblocks to adopting the open innovation model are identified as well as ways to overcome these roadblocks. This conceptual paper makes use of archival R&D and sales data to support its contentions.

Original languageEnglish
Pages (from-to)63-74
Number of pages12
JournalInternational Journal of Business Innovation and Research
Volume5
Issue number1
DOIs
StatePublished - 1 Jan 2011

Keywords

  • Open innovation
  • Pharmaceutical industry
  • R&D
  • Research and development

Fingerprint Dive into the research topics of 'The evolution of research and development in the pharmaceutical industry: Toward the open innovation model - Can pharma reinvent itself?'. Together they form a unique fingerprint.

  • Cite this